Phase 2 N=18 Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients
Fabry Disease
Primary: Adverse Events — 54; 11; 29; 14 adverse events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=383 Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis
Colitis, Ulcerative
Primary: Percentage of Participants Achieving Clinical Remission at Week 52 — 14.3; 46.2; 42.6 percentage of participants — p=<0.001
Phase 3 N=37 Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation (REVERSE)
Optic, Atrophy, Hereditary, Leber
Primary: Change From Baseline in ETDRS Visual Acuity (Quantitative Score) at Week 48 — -0.219; -0.211 LogMAR — p=0.8783
Phase 2 N=56 Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
Pediatric Growth Hormone Deficiency
Primary: Annual Height Velocity — 10.4; 11.0; 11.9; 12.5 cm/year
Phase 4 N=54 Liposomal Bupivacaine After Arthroscopic Rotator Cuff Repair
Rotator Cuff Tear
Primary: Numeric Rating Pain Score [NRS] at Time of Block Resolution — 5.4; 5.8 Score on a scale — p=0.66
Phase 1 N=30 Bioavailability of Apixaban Sprinkle Compared to Apixaban Capsules
Healthy Volunteers
Primary: Concentration as Measured by Maximum Observed Plasma Concentration (Cmax) — 77.4; 99.3 ng/mL
Phase 3 N=21 Standard Lipid Therapy vs IVFE Minimization for Prevention of PNALD
Cholestasis
Primary: Rate of Rise of Direct Bilirubin as a Function of Time — 1.033001353; 1.05457485; 1.025504411; 1.049318179 mg/dL/day
N/A N=104 Can we Reduce Hospital Attendance Without Compromising Care by the Use of Telephone Consultation
Asthma · COPD · Sleep Apnea Syndromes
Primary: Patient Satisfaction — 114.3; 116.8 score on scale — p=0.064
N/A N=80 Clinical Trial to Evaluate the Efficacy of Bifidobacterium BB-12® in the Treatment of Infantile Colic
Infantile Colic · Colic, Infantile
Primary: Number of Participants With >=50% Reduction in Mean Weekly Crying Duration — 32; 13; 3; 24 Participants — p=0.0001
Phase 3 N=66 Stopping Cavities Study: Diammine Silver Fluoride
Dental Caries
Primary: Dental Caries Activity — .72; .05 Proportion of arrested caries lesions
N/A N=20 Early Speech With One-Way Speaking Valve in Tracheostomy Patients
Respiratory Failure · Speech · Aphonia
Primary: Speech Intelligibility as Assessed by Speech Intelligibility Test Score — 25.71; 0 Percentage of intelligible words
Phase 2 N=15 Oral Nitrite for Older Heart Failure With Preserved Ejection Fraction
Heart Failure
Primary: Cardiorespiratory Fitness — 4.1; 4.0; 5.1; 4.5 ml/kg/min
Phase 2 N=65 Alzheimer's Disease: Potential Benefit of Isoflavones
Alzheimer's Disease
Primary: Cognitive Outcomes - Language Executive Function : Category Fluency Assessed as Number of Words Generated/Min — 21.5; 25.7 number of words generated per minute
N/A N=20 The Insulin-Only Bionic Pancreas Bridging Study- Pediatric Transitional Study
Type1 Diabetes Mellitus
Primary: Mean CGM Glucose — 159; 163 mg/dl
N/A N=31 A Technology-Enhanced Approach for Implementing Evidence-Based Practices in Child Welfare
Child Maltreatment · Implementation · Technology
Primary: Number of Providers Reporting Satisfaction With Technology — 14 Participants